News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
205,331 Results
Type
Article (9708)
Company Profile (43)
Press Release (195579)
Multimedia
Podcasts (12)
Webinars (5)
Section
Business (65105)
Career Advice (278)
Deals (12615)
Drug Delivery (32)
Drug Development (24878)
Employer Resources (69)
FDA (4665)
Job Trends (5230)
News (105405)
Policy (7909)
Tag
2027 Pharm Country Standard (1)
Academia (658)
Accelerated approval (15)
Adcomms (3)
Allergies (62)
Alliances (9495)
ALS (43)
Alzheimer's disease (527)
Antibody-drug conjugate (ADC) (127)
Approvals (4891)
Artificial intelligence (101)
Autoimmune disease (72)
Automation (10)
Bankruptcy (78)
Best Places to Work (4432)
BIOSECURE Act (2)
Biosimilars (52)
Biotechnology (26)
Bladder cancer (70)
Brain cancer (31)
Breast cancer (263)
Cancer (1842)
Cardiovascular disease (184)
Career advice (234)
Career pathing (7)
CAR-T (72)
CDC (12)
Cell therapy (206)
Cervical cancer (11)
Clinical research (22503)
Collaboration (385)
Company closure (2)
Compensation (892)
Complete response letters (18)
COVID-19 (816)
CRISPR (21)
C-suite (296)
Cystic fibrosis (61)
Data (2670)
Denatured (1)
Depression (43)
Diabetes (194)
Diagnostics (2063)
Digital health (12)
Diversity (1)
Diversity, equity & inclusion (16)
Drug discovery (73)
Drug pricing (49)
Drug shortages (8)
Duchenne muscular dystrophy (87)
Earnings (42807)
Editorial (12)
Employer branding (6)
Employer resources (58)
Events (29911)
Executive appointments (337)
FDA (5840)
Fibrodysplasia Ossificans Progressiva (3)
Friedreich's ataxia (4)
Frontotemporal dementia (11)
Funding (453)
Gene editing (45)
Generative AI (8)
Gene therapy (172)
GLP-1 (378)
Government (1178)
Grass and pollen (3)
Guidances (337)
Healthcare (6365)
HIV (26)
Huntington's disease (10)
IgA nephropathy (47)
Immunology and inflammation (79)
Immuno-oncology (18)
Indications (53)
Infectious disease (914)
Inflammatory bowel disease (67)
Inflation Reduction Act (4)
Influenza (36)
Intellectual property (56)
Interviews (41)
IPO (7856)
IRA (7)
Job creations (974)
Job search strategy (208)
JPM (16)
Kidney cancer (10)
Labor market (35)
Layoffs (180)
Leadership (5)
Legal (1504)
Liver cancer (25)
Longevity (4)
Lung cancer (263)
Lymphoma (185)
Machine learning (9)
Management (23)
Manufacturing (188)
MASH (57)
Medical device (4444)
Medtech (4465)
Mergers & acquisitions (5199)
Metabolic disorders (489)
mRNA (50)
Multiple sclerosis (74)
NASH (6)
Neurodegenerative disease (103)
Neuropsychiatric disorders (30)
Neuroscience (946)
NextGen: Class of 2026 (1688)
Non-profit (1259)
Now hiring (7)
Obesity (229)
Opinion (58)
Ovarian cancer (68)
Pain (54)
Pancreatic cancer (72)
Parkinson's disease (108)
Partnered (7)
Patents (110)
Patient recruitment (109)
Peanut (26)
People (14793)
Pharmaceutical (10)
Pharmacy benefit managers (4)
Phase 1 (5990)
Phase 2 (9727)
Phase 3 (8806)
Pipeline (3137)
Policy (47)
Postmarket research (796)
Preclinical (1929)
Press Release (9)
Prostate cancer (80)
Psychedelics (10)
Radiopharmaceuticals (96)
Rare diseases (308)
Real estate (1299)
Recruiting (30)
Regulatory (6623)
Reports (24)
Research institute (665)
Resumes & cover letters (50)
Rett syndrome (11)
RNA editing (6)
RSV (26)
Schizophrenia (47)
Series A (62)
Series B (44)
Service/supplier (3)
Sickle cell disease (31)
Special edition (12)
Spinal muscular atrophy (77)
Sponsored (13)
Startups (856)
Stomach cancer (4)
Supply chain (26)
Tariffs (33)
The Weekly (11)
Vaccines (335)
Venture capital (22)
Weight loss (160)
Women's health (21)
Worklife (4)
Date
Today (53)
Last 7 days (226)
Last 30 days (1287)
Last 365 days (11195)
2026 (2271)
2025 (11269)
2024 (11742)
2023 (13116)
2022 (30246)
2021 (17359)
2020 (15477)
2019 (13181)
2018 (10058)
2017 (9135)
2016 (8063)
2015 (9870)
2014 (6845)
2013 (5295)
2012 (5455)
2011 (5872)
2010 (4981)
Location
Africa (188)
Alabama (62)
Alaska (1)
Arizona (70)
Arkansas (4)
Asia (11819)
Australia (1889)
California (4320)
Canada (1278)
China (375)
Colorado (146)
Connecticut (160)
Delaware (156)
Europe (28039)
Florida (562)
Georgia (127)
Hawaii (1)
Idaho (12)
Illinois (246)
India (23)
Indiana (288)
Iowa (4)
Japan (182)
Kansas (40)
Kentucky (10)
Louisiana (12)
Maine (28)
Maryland (526)
Massachusetts (2879)
Michigan (114)
Minnesota (180)
Mississippi (2)
Missouri (36)
Montana (11)
Nebraska (7)
Nevada (37)
New Hampshire (29)
New Jersey (1273)
New Mexico (3)
New York (1050)
North Carolina (494)
North Dakota (1)
Northern California (2213)
Ohio (69)
Oklahoma (2)
Oregon (6)
Pennsylvania (911)
Puerto Rico (3)
Rhode Island (3)
South America (293)
South Carolina (15)
Southern California (1754)
Tennessee (75)
Texas (650)
United States (14773)
Utah (110)
Virginia (92)
Washington D.C. (11)
Washington State (313)
West Virginia (2)
Wisconsin (25)
205,331 Results for "25".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Immunology and inflammation
J&J Stops Mid-stage Eczema Trial as $1.25B Asset Misses Efficacy Mark
J&J paid Numab Therapeutics $1.25 billion upfront for the asset in 2024 based on the belief that its dual mechanism of action could improve on existing therapies.
January 5, 2026
·
2 min read
·
Nick Paul Taylor
Press Releases
IBA – TRANSPARENCY NOTIFICATION - February 25, 2026
February 26, 2026
·
2 min read
Press Releases
$25 Million Project Seeks to Coordinate Data Produced by Human-Based Testing Methods
March 19, 2026
·
4 min read
Press Releases
For the First Time, Ferring Reports Revenue of Over €2.5 Billion in 2025
March 10, 2026
·
3 min read
Press Releases
Opus Genetics Announces $25 Million Private Placement
February 13, 2026
·
5 min read
Press Releases
Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026
March 18, 2026
·
2 min read
Press Releases
Bright Minds Biosciences to Present at Upcoming Conferences - February 25, 2026
February 26, 2026
·
1 min read
Press Releases
SeaStar Medical to Report Fourth Quarter and Year-End 2025 Financial Results on March 25, 2026
March 18, 2026
·
1 min read
Press Releases
Trinity Biotech Secures $25 Million Financing Commitment to Support Growth Initiatives
February 25, 2026
·
6 min read
Mergers & acquisitions
Servier Adds to Childhood Brain Tumor Portfolio With $2.5B Day One Buy
Servier will pick up Ojemda, which received FDA approval in 2024 to treat pediatric glioma. The drug clocked sales of $155 million for Day One Biopharmaceuticals in 2025.
March 6, 2026
·
1 min read
·
Annalee Armstrong
1 of 20,534
Next
